接受间歇性化疗的恶性淋巴瘤患者的家庭症状管理:使用网络分析进行前性观察性研究
Qinglu Li1, Lu Yang2, Nan Wang1
1College of Nursing, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Asia-Pacific journal of oncology nursing
|April 24, 2025
概括
这项研究确定了缺乏食欲,悲伤和恶心是化学疗法休息期间恶性淋巴瘤患者的关键症状. 专注于这些核心症状可以改善家庭护理和患者的福祉.
科学领域:
- 在瘤学瘤学.
- 症状科学 症状科学
- 网络分析 网络分析
背景情况:
- 恶性淋巴瘤患者在间歇性化疗周期中经历了显著的症状负担.
- 了解症状动态对于有效的家庭护理和患者支持至关重要.
研究的目的:
- 探索恶性淋巴瘤患者在家庭间歇性化疗期间的症状负担.
- 通过网络分析识别核心症状,以进行有针对性的症状管理.
主要方法:
- 一项前性观察性研究包括从2019年12月到2020年12月的208名患者.
- 在三个时间点使用MD Anderson症状目录-中文版本 (MDASI-C) 评估了症状负担.
- 对核心和桥梁症状构建和分析症状网络,并使用网络比较测试 (NCT) 来检查随时间变化.
主要成果:
- 疲劳和吐分别是最常见和最严重的症状.
- 缺乏食欲,悲伤和恶心被确定为不同时间点 (T1,T2,T3) 的核心症状.
- 在T2期间,悲伤在症状网络中发挥了更大的中心作用,这表明它越来越重要.
结论:
- 缺乏食欲,悲伤和恶心是接受化疗的淋巴瘤患者症状管理的关键目标.
- 医疗保健提供者和护理人员应优先考虑这些症状,以加强家庭症状管理.
- 改善这些核心症状的管理可以显著提高患者在治疗期间的幸福感.
相关概念视频
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Cancer Survival Analysis
298
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
298
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
134
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
134


